Last reviewed · How we verify
RG4733
At a glance
| Generic name | RG4733 |
|---|---|
| Also known as | RO4929097 |
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer (PHASE1, PHASE2)
- A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RG4733 CI brief — competitive landscape report
- RG4733 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI